Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?

Aurinia Pharmaceuticals (AUPH) shares ended the last trading session 6.6% higher at $5.86. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.9% gain over the past four weeks.The rise in share price was attributable to positive investor expectations for Lupkynis, the company’s sole marketed drug which is approved for treatment of adults with active lupus nephritis (LN). Sales of the drug are being driven predominant ...